title: Defining the optimal dosage of methotrexate for childhood acute lymphoblastic leukemia. New insights from the lab and clinic.
authors.affiliation: Department of Pharmaceutical Sciences and Hematology-Oncology, St. Jude Children's Research Hospital, University of Tennessee, Colleges of Pharmacy and Medicine, Memphis 38105, USA.
authors.forename: W E
authors.initials: WE
authors.lastname: Evans
authors.forename: C H
authors.initials: CH
authors.lastname: Pui
authors.forename: M V
authors.initials: MV
authors.lastname: Relling
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D002648:Child; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D011003:Ploidies; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics
chemical_list: D000964:Antimetabolites, Antineoplastic; D008727:Methotrexate